Latest Close
₹2,244.00
+4.76%
Connecting…
Day Range
-
Full OHLC pending
Volume
-
Full session data pending
50 DMA
₹1,902.89
200 DMA
₹1,369.68
1 year gain / loss
+₹1,273.65(+131.26%)
₹970.35 → ₹2,244.00· 2025-10-30 to 2026-10-30
Charting by TradingView
This stock does not satisfy the default swing-support rules at the selected chart endpoint. Its price, volume and moving averages remain available for manual research.
Snapshot 2026-11-01 · Financial period Sep 2026 · Consolidated figures where available
Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The Company offers an integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry. It operates through four divisions: Generics API, Generics FDF, CDMO custom synthesis (Laurus Synthesis), and Biotechnology (Laurus Bio). The Generics API is a third-party API supplier for antiretrovirals. The Generic FDF business focuses on oral solid formulations. Laurus Synthesis provides drug development and manufacturing services to global pharma, crop science, animal health, and others. Laurus Bio offers comprehensive services from clone and strain engineering to production, supporting clients across the microbial precision fermentation spectrum. Its solutions cater for sectors, such as regenerative medicine, vaccines, cultured meat, and others.
Market Cap
₹1,29,242.68 Cr
P/E
97.00×
Sector -38.72× · above
P/B
21.33×
Sector 4.11× · above
EV / EBITDA
54.77×
Sector 22.21× · above
ROE
22.11%
Sector 0.31%
ROCE
20.91%
Sector 6.48%
ROA
11.58%
Sector -17.12%
Cash Flow / Profit
1.82×
| Period | Revenue | Operating profit | Net profit |
|---|---|---|---|
| Sep 2026 | 2,219.38 +9.0% | 591.82 | 436.74 +20.6% |
| Jun 2026 | 2,035.49 +11.6% | 481.36 | 361.99 +28.4% |
| Mar 2026 | 1,823.37 +2.2% | 361.37 | 281.91 +11.4% |
| Dec 2025 | 1,784.05 | 326.56 | 253.11 |
Dividend
08 May 2026 · ₹1.2